China Genetic Engineering Drug Industry Report, 2011-2012

NEW YORK, July 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Genetic Engineering Drug Industry Report, 2011-2012

http://www.reportlinker.com/p0934677/China-Genetic-Engineering-Drug-Industry-Report-2011-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharma

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs. In recent years, the compound growth rate of genetic engineering drug market in China is as high as 49%, with an average gross margin of more than 80%. However, the technology strength and efficacy of locally produced genetic engineering drugs are relatively weak. In particular, the pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) for injection of CSPC Pharmaceutical Group Limited that approved for marketing in March 2012 is the only homemade long-acting protein product. Still, due to the impetus of huge market capacity as well as a package of preferential policies, many domestic enterprises, including GeneScience Pharmaceuticals, Amoytop and Anhui Anke Biotechnology, are accelerating the industrialized research of long-acting protein drugs.

Monoclonal antibody is one of the most promising genetic engineering drugs. As of May 2012, SFDA approved the marketing of a total of 18 monoclonal antibody drugs. Among these drugs, nearly 60% are foreign brands including Roche, Merck and Novartis with the combined sales accounting for three fourths of the Chinese monoclonal antibody drug market. However, with the marketing of monoclonal antibody drugs made by companies such as Shanghai CP Guojian Pharmaceutical and Biotech Pharmaceutical, the market share of homemade monoclonal antibody industry is on the rise gradually.

In addition, recombinant human erythropoietin, recombinant human interferon, recombinant human growth hormone, recombinant human granulocyte-colony stimulating factor and recombinant human insulin are among the important genetic engineering drugs. As of late 2011, China had roughly 20 recombinant EPO manufacturers that approved for marketing of related products. In particular, as former EPO preparation exporters to China, enterprises including America-based Amgen and Germany-based Boehringer Mannheim GmbH have withdrawn from the Chinese market owning to low price competition. Presently, the Chinese EPO market is dominated by domestic manufacturers including 3SBio Inc. and DIAO Group. In 2011, the sales of 3SBio Inc. accounted for 42.7% in China's EPO market. As such, impacted by channel, price competition and other factors, recombinant human growth hormone and recombinant human granulocyte-colony stimulating factor markets are also dominated by domestic enterprises.

In the recombinant human interferon market, the high-performance long-acting interferon of Schering-Plough and Roche still maintained huge consumption in Chinese market in spite of the high prices. In recent years, the market share of imported long-acting interferon has remained at 60% or so in China.

Moreover, due to improving economic level and raising awareness of people, foreign-branded recombinant human insulin in Chinese market are predominant, occupying 90% market share in the corresponding period.

Although China lags behind in terms of the overall level of genetic engineering drugs, the industry has accumulated rich R&D and industrialization experience as well as capital reserves. Thus, with a host of genetic engineering drug patents to become due, Chinese enterprises, such as Walvax, are committed to the industrialization research of monoclonal antibody, long-acting recombinant protein drugs and other generic drugs with high technical barriers. On April 26th, 2012, Walvax announced to invest in Shanghai Fengmao in next four years to develop and produce genetic engineering generic drugs including rituximab, bevacizumab, adalimumab, panitumumab, denosumab and long-acting EPO.

Papermaking

Selected Charts

Classification of Biopharmaceutical ProductsClassification of Genetic Engineering DrugsSales of Amgen's Four Genetic Engineering Drugs, 2009-2011R&D Cost of Main Biopharmaceutical Enterprises in the World, 2009-2011Competition Pattern of Genetic Engineering Drugs in China, 2011Comparison between China, USA and Japan by Commercialization Schedule of Some Genetic Engineering Protein DrugsExpiration Date of Main Genetic Engineering Drug Patents in the WorldMonoclonal Antibody Drugs Approved for Marketing in China, As of 2012Sales of Monoclonal Antibody Drugs in China, 2008-2011Some Listed Companies Investing in Monoclonal Antibody Industry in China, 2009-2012Sales Volume and Value of EPO in China, 1999-2011Competition Pattern of EPO in China (by Sales Volume or Value), 2007-2011Market Size of rh-IFN in China, 2006-2011Market Share of Major rh-IFN Injection Enterprises in China by Sales, 2006-2008Market Capacity Forecast of rh-IFN for Hepatitis Therapy in ChinaComparison Between Long-acting IFN and Conventional IFNMarket Share of Major rh-GH Enterprises in China, 2006-2008Market Capacity Forecast of rh-GH for Short Stature Therapy in ChinaMarket Prices of Common Insulin Products in China, 2010-2011Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in China, 2008-2011 Market Share of rhG-CSF Enterprises in China, 2010Major Monoclonal Antibody Product Line under Research of Shanghai Lansheng Guojian PharmaceuticalRevenue and Net Income of Shanghai CP Guojian Pharmaceutical, 2008-2010Monoclonal Antibody Product Series under Research of Shanghai CP Guojian PharmaceuticalUnder-research Monoclonal Antibody Projects of Beijing BiotechRevenue and Profit of ANKE BIO, 2007-2011ANKE BIO's Revenue Breakdown by Industry, 2007-2012ANKE BIO's Revenue Percentage by Industry, 2007-2012ANKE BIO's Revenue Breakdown by Region, 2007-2011ANKE BIO's Revenue Percentage by Region, 2007-2011ANKE BIO's Gross Margin by Industry, 2007-2011ANKE BIO's Revenue from Top 5 Clients and % of Total Revenue, 2007-2011Name List and Revenue Contribution of ANKE BIO's Top 5 Clients, 2011ANKE BIO's Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2011R&D Costs and % of Total Revenue of ANKE BIO, 2007-2011ANKE BIO's Revenue from Interferon and Growth Hormone, 2007-2011ANKE BIO's Gross Margin from Interferon and Growth Hormone, 2007-2011Revenue and Operating Income of GenSci, 2009-2011Research Schedule of GenSci's Genetic Engineering Drugs, As of 2011Revenue and Operating Income of SL Pharmaceutical, 2007-2012SL Pharmaceutical's Revenue and Procurement from Top5 Clients and Suppliers, 2008-2011SL Pharmaceutical's Revenue Breakdown by Products, 2008-2011SL Pharmaceutical's Revenue Percentage by Products, 2008-2011SL Pharmaceutical's Revenue Breakdown by Region, 2008-2011SL Pharmaceutical's Gross Margin by Products, 2008-2011R&D Costs and % of Total Revenue of SL Pharmaceutical, 2008-2011Revenue and Operating Income of Sihuan Bioengineering, 2008-2012Sihuan Bioengineering's Operating Revenue by Region, 2008-2011Sihuan Bioengineering's Revenue from Interleukin and EPO, 2008-2011Sihuan Bioengineering's Gross Margin from Interleukin and EPO, 2008-2011Revenue and Profit of Beijing Four Rings, 2008-2011Revenue and Profit of Neptunus Interlong Bio-Technique, 2008-2012Neptunus Interlong Bio-Technique's Revenue Breakdown by Business, 2008-2011Products List of 3SBio Inc.Revenue and Profit of 3SBio Inc., 2007-20123SBio Inc.'s Revenue Breakdown by Product/Region, 2009-20123SBio Inc.'s Revenue Percentage by Products, 2009-20113SBio Inc.'s Revenue Percentage by Region, 2009-2012R&D Cost of 3SBio Inc. by Products, 2009-2011Research Schedule of 3SBio Inc. , As of Mar., 2012Revenue and Profit of THDB, 2008-2012THDB's Revenue Breakdown by Products, 2008-2011THDB's Revenue Percentage by Products, 2008-2011THDB's Revenue Breakdown by Region, 2008-2011THDB's Revenue Percentage by Region, 2008-2011THDB's Gross Margin by Products, 2008-2011THDB's Revenue from Top 5 Clients and % of Total Revenue, 2008-2011Name List and Revenue Contribution of THDB's Top 5 Clients, 2011Revenue and Gross Margin of THDB's Recombinant Human Insulin, 2008-2011Research Schedule of Amoytop Biotech's Long-acting Recombinant Protein Drugs, As of 2011To order this report:Biopharmaceutical Industry: China Genetic Engineering Drug Industry Report, 2011-2012More  Market Research ReportCheck our  Industry Analysis and Insights

CONTACT
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker